73/100BHaleon company profile
- CEO
- Brian James McNamara
- Employees
- 24,535
- Headquarters
- The Heights, Weybridge, SU KT13 0NY, GB
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- IPO date
- 25 Jul 2022
- Stock exchange
- NYSE
- ISIN
- US4055521003
Website:haleon.com
About the company
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.
Employees
Haleon had about 0 employees at the end of fiscal year 2025 (31 December 2025), by its annual report. That is 100.0% fewer than a year before.
Employees at each fiscal year end, as the company reports them in its annual report (10-K); revenue and net income per employee are the fiscal year's over that count.
Who owns Haleon
Institutions such as funds, banks and insurers held 13.2% of Haleon's shares on 30 June 2026, 654 of them reporting holdings to the SEC; the rest is held by individual investors and other shareholders.
Shares free to trade
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Common questions about Haleon
Source: Financial Modeling Prep